TY - JOUR T1 - Risk factors for infection, predictors of severe disease and antibody response to COVID-19 in patients with rheumatic diseases in Portugal – a multicentre, nationwide study JF - medRxiv DO - 10.1101/2021.10.01.21264428 SP - 2021.10.01.21264428 AU - Ana Rita Cruz-Machado AU - Sofia C Barreira AU - Matilde Bandeira AU - Marc Veldhoen AU - Andreia Gomes AU - Marta Serrano AU - Catarina Duarte AU - Maria Rato AU - Bruno Miguel Fernandes AU - Salomé Garcia AU - Filipe Pinheiro AU - Miguel Bernardes AU - Nathalie Madeira AU - Cláudia Miguel AU - Rita Torres AU - Ana Bento Silva AU - Jorge Pestana AU - Diogo Almeida AU - Carolina Mazeda AU - Filipe Cunha Santos AU - Patrícia Pinto AU - Marlene Sousa AU - Hugo Parente AU - Graça Sequeira AU - Maria José Santos AU - João Eurico Fonseca AU - Vasco C Romão Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/03/2021.10.01.21264428.abstract N2 - In order to identify risk factors for SARS-CoV-2 infection as well as for severe/critical COVID-19 in rheumatic and musculoskeletal diseases (RMDs) patients, we conducted a multicentre observational nationwide study of adult patients prospectively-followed in the Rheumatic Diseases Portuguese Register – Reuma.pt – during the first 6 months of the pandemic. We further evaluated the development of IgG antibodies against the receptor-binding domain (RBD) of SARS-CoV-2 in patients with RMDs. We used multivariate logistic regression to compare patients with COVID-19 (COVID-19+) with those who did not develop the disease (COVID-19-) and patients with mild/moderate disease with those exhibiting severe/critical COVID-19. COVID-19+ patients were asked to collect a blood sample for IgG testing ≥ 3 months after infection and results were compared with age-, sex- and sampling date-matched controls. Overall, 179 cases of COVID-19 were registered in Reuma.pt in the period of interest (median age 55 (IQR 20); 76.5% females) in a total of 6404 registered appointments. We found that patients treated with TNF inhibitors had reduced odds of infection (OR=0.16, 95%CI 0.10-0.26, p<0.001), severe disease (OR 0.11, 95%CI 0.01-0.84, p=0.010) and seroconversion rates (OR 0.13, 95%CI 0.02-0.91, p=0.040). Tocilizumab was also associated with a reduced risk of COVID-19 (OR 0.15, 95%CI 0.05-0.41, p<0.001). Older age, major comorbidities (diabetes, hypertension, obesity, cardiovascular disease, chronic pulmonary and kidney disease) and rituximab were associated with an increased risk of infection and worse prognosis, in line with previous reports. Importantly, most patients with inflammatory RMDs (86.2%) were able to develop a robust antibody response after SARS-CoV-2 infection, which was linked with disease severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would like to acknowledge Merck Sharp & Dohme for funding this entire project. Regarding funding sources of the laboratory, we also would like to acknowledge Sociedade Francisco Manuel dos Santos and Grupo Jeronimo Martins, the European Union Horizon 2020 research and innovation program and Fundacao para a Ciencia e a Tecnologia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Lisbon Academic Medical Centre and all patients signed informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in the manuscript are available upon request to the corresponding author. ER -